The website lists CaDAnCe-302 for tacabrutideg/BGB-16673 as Phase 3. CDAC is the company's term for chimeric degradation-activating compounds.
Mainland China / United States / SwitzerlandFull profile →
Company database
Profiles, sources, and comparisons are open. Choose a field on the left to see its companies.
Search & refine Filters update automatically
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
473 matching companiesShowing 121–144 / 473
GT20029 is a topical AR PROTAC. A 2024 announcement reports that the China Phase 2 male androgenetic alopecia study met its primary endpoint.
Mainland ChinaFull profile →
An original 2025 ESMO abstract describes QLH12016 as an oral AR PROTAC, with data through February 2025 from 36 patients with mCRPC.
Mainland ChinaFull profile →
An April 2025 website announcement identifies TQB3019 as the OAPD platform's first oral BTK PROTAC and reports Chinese clinical authorization.
Mainland ChinaFull profile →
The official pipeline explicitly lists HJ-002 and HJ-004 as EGFR PROTACs for NSCLC and advanced cancers, respectively.
Mainland ChinaFull profile →
The website lists NanoBRET/TR-FRET/SPR and HiBiT/JESS platforms for permeability, target engagement, ternary complexes, and quantitative degradation kinetics.
United StatesFull profile →
A dedicated page describes E1/E2/E3 and deubiquitinase assays for the ubiquitin–proteasome system, plus PROTAC evaluation from ternary complexes to degradation kinetics and selectivity.
Mainland ChinaFull profile →
Develops the LUNAR lipid delivery and STARR self-amplifying mRNA platforms. KOSTAIVE is an approved sa-mRNA COVID-19 vaccine.
United StatesFull profile →
Active in nucleic acid synthesis since 1996; a Maravai-owned CDMO supplying mRNA, NTPs, and CleanCap capping reagents.
United StatesFull profile →
CHARMED provides parallel synthesis with common E3 ligands and linkers, degradation screening, and early ADME. The website identifies an SHP2 degrader collaboration with Japan's UBE.
United KingdomFull profile →
Founded in 2009, this LNP delivery technology company advances nucleic acid drug delivery R&D and commercialization primarily through partners. Licensed platforms are not classified as company-owned drug candidates.
CanadaFull profile →
An official technical poster describes development of bifunctional degraders using novel E3 ligases and construction of molecular glue libraries.
GermanyFull profile →
The website offers CRBN/VHL/IAP degrader design and synthesis, binary / ternary binding, NanoBRET, HiBiT, ubiquitination, and direct-to-biology workflows, and lists a collaboration with Amphista.
United KingdomFull profile →
The company explicitly accepts FFS, cost-sharing, and FTE models. Its dedicated page lists validated assays for BRD4, KRAS, CRBN/VHL binding, and ternary complexes.
United StatesFull profile →
The website explicitly offers PROTAC and molecular glue screening and drug discovery support, describing assay systems for degradation research.
United KingdomFull profile →
A dedicated R&D Systems page explicitly offers custom active-degrader design / synthesis, building-block panels, and E3 ligase development, including a Tocris client case.
United StatesFull profile →
On 2026-08-13, FDA granted accelerated approval to iberdomide (Zenbexus) with daratumumab/hyaluronidase-fihj and dexamethasone for certain previously treated multiple myeloma patients. It is a CRBN-modulating CELMoD.
United StatesFull profile →
On 2026-06-08, Roche announced joint development and commercialization with Nurix of the oral BTK degrader bexobrutideg (NX-5948), with CLL Phase 3 planned for summer 2026.
SwitzerlandFull profile →
Kymera's Q2 2026 update reports that Sanofi began first-in-human Phase 1 KT-485 (SAR447971), an oral IRAK4 degrader, in June. Sanofi is responsible for subsequent development, regulatory work, and commercialization.
FranceFull profile →
DT2216 is a VHL-recruiting BCL-XL PROTAC. An original 2025 Phase 1 paper in 20 patients reports human PK and peripheral leukocyte BCL-XL reduction. NCI lists combination studies in ovarian and fibrolamellar liver cancers.
United StatesFull profile →
An original joint announcement with Photys on 2026-08-13 reports Phase 1 healthy-volunteer dosing of HPB-143/PHT-776. Polymed licensed development and commercialization rights outside Greater China and Southeast Asia to Photys.
Mainland ChinaFull profile →
An original Nurix announcement on 2026-09-29 reports a research milestone in the Pfizer DAC collaboration. Pfizer handles antibody conjugation and subsequent development. Global vepdegestrant development, manufacturing, and commercialization rights transferred to Rigel in June 2026.
United StatesFull profile →
Lilly's website lists LY4584180 as an oral, monovalent BCL6 polymerizing molecular glue. Phase 1 NOVA-BCL6-1, NCT07226843, is recruiting; UCSF's trial page records an April 2026 start.
United StatesFull profile →
A dedicated official page offers PROTAC and partial-PROTAC synthesis, E3 ligand / linker design, molecular glues, ternary-complex and cellular degradation evaluation, and custom ADME/PK and toxicology services, through standalone or integrated projects.
IndiaFull profile →
Coverage expands from sourced records; this database does not claim all biopharma companies.